Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome

B. E. Harris, J. T. Carpenter, Robert B Diasio

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

This study describes the inheritance of a defect in pyrimidine catabolism and its association with drug-induced toxicity in a patient receiving 5-fluorouracil (FUra) as adjuvant chemotherapy for breast carcinoma. The study population included the affected patient (proband), nine of her blood relatives, and seven healthy volunteers. The activity of dihydropyrimidine dehydrogenase (DPD), the initial enzyme of pyrimidine (and FUra) catabolism, in peripheral blood mononuclear cells was measured in each subject by a specific radiometric assay using FUra as the substrate. The proband had no detectable DPD activity. When enzyme levels in the proband and relatives were compared with that in controls, an autosomal recessive pattern of inheritance was demonstrated. This is the third patient with severe FUra toxicity secondary to an alteration in pyrimidine catabolism and the second from our clinic population suggesting that the frequency of this genetic defect may be greater than previously thought. Monitoring DPD activity may be important in the management of patients experiencing severe toxicity secondary to FUra chemotherapy.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalCancer
Volume68
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Dihydropyrimidine Dehydrogenase Deficiency
Pharmacogenetics
Fluorouracil
Dihydrouracil Dehydrogenase (NADP)
Inheritance Patterns
Enzymes
Adjuvant Chemotherapy
Drug-Related Side Effects and Adverse Reactions
Population
Blood Cells
Healthy Volunteers
Breast Neoplasms
Drug Therapy
pyrimidine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency : A potentially more common pharmacogenetic syndrome. / Harris, B. E.; Carpenter, J. T.; Diasio, Robert B.

In: Cancer, Vol. 68, No. 3, 1991, p. 499-501.

Research output: Contribution to journalArticle

@article{f5b59618e8a44e4d9f100f777930d82f,
title = "Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome",
abstract = "This study describes the inheritance of a defect in pyrimidine catabolism and its association with drug-induced toxicity in a patient receiving 5-fluorouracil (FUra) as adjuvant chemotherapy for breast carcinoma. The study population included the affected patient (proband), nine of her blood relatives, and seven healthy volunteers. The activity of dihydropyrimidine dehydrogenase (DPD), the initial enzyme of pyrimidine (and FUra) catabolism, in peripheral blood mononuclear cells was measured in each subject by a specific radiometric assay using FUra as the substrate. The proband had no detectable DPD activity. When enzyme levels in the proband and relatives were compared with that in controls, an autosomal recessive pattern of inheritance was demonstrated. This is the third patient with severe FUra toxicity secondary to an alteration in pyrimidine catabolism and the second from our clinic population suggesting that the frequency of this genetic defect may be greater than previously thought. Monitoring DPD activity may be important in the management of patients experiencing severe toxicity secondary to FUra chemotherapy.",
author = "Harris, {B. E.} and Carpenter, {J. T.} and Diasio, {Robert B}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "499--501",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency

T2 - A potentially more common pharmacogenetic syndrome

AU - Harris, B. E.

AU - Carpenter, J. T.

AU - Diasio, Robert B

PY - 1991

Y1 - 1991

N2 - This study describes the inheritance of a defect in pyrimidine catabolism and its association with drug-induced toxicity in a patient receiving 5-fluorouracil (FUra) as adjuvant chemotherapy for breast carcinoma. The study population included the affected patient (proband), nine of her blood relatives, and seven healthy volunteers. The activity of dihydropyrimidine dehydrogenase (DPD), the initial enzyme of pyrimidine (and FUra) catabolism, in peripheral blood mononuclear cells was measured in each subject by a specific radiometric assay using FUra as the substrate. The proband had no detectable DPD activity. When enzyme levels in the proband and relatives were compared with that in controls, an autosomal recessive pattern of inheritance was demonstrated. This is the third patient with severe FUra toxicity secondary to an alteration in pyrimidine catabolism and the second from our clinic population suggesting that the frequency of this genetic defect may be greater than previously thought. Monitoring DPD activity may be important in the management of patients experiencing severe toxicity secondary to FUra chemotherapy.

AB - This study describes the inheritance of a defect in pyrimidine catabolism and its association with drug-induced toxicity in a patient receiving 5-fluorouracil (FUra) as adjuvant chemotherapy for breast carcinoma. The study population included the affected patient (proband), nine of her blood relatives, and seven healthy volunteers. The activity of dihydropyrimidine dehydrogenase (DPD), the initial enzyme of pyrimidine (and FUra) catabolism, in peripheral blood mononuclear cells was measured in each subject by a specific radiometric assay using FUra as the substrate. The proband had no detectable DPD activity. When enzyme levels in the proband and relatives were compared with that in controls, an autosomal recessive pattern of inheritance was demonstrated. This is the third patient with severe FUra toxicity secondary to an alteration in pyrimidine catabolism and the second from our clinic population suggesting that the frequency of this genetic defect may be greater than previously thought. Monitoring DPD activity may be important in the management of patients experiencing severe toxicity secondary to FUra chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025990479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025990479&partnerID=8YFLogxK

M3 - Article

C2 - 1648430

AN - SCOPUS:0025990479

VL - 68

SP - 499

EP - 501

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -